Gilead Sciences, Inc. (GILD) - Technical Look

Marco Green
November 14, 2017

Atria Invests stated it has 15,137 shares or 0.07% of all its holdings. The company exchanged hands with 12642046 shares compared to its average daily volume of 9.99M shares. Paradigm Cap Mgmt Incorporated invested 0.02% of its portfolio in Abbott Laboratories (NYSE:ABT). The Brave Asset Management Inc holds 4,000 shares with $284,000 value, down from 30,621 last quarter. Neuberger Berman Limited Liability invested in 2.58M shares or 0.23% of the stock. Spears Abacus Ltd Liability, New York-based fund reported 320,064 shares. They expect $1.67 EPS, down 36.74% or $0.97 from last year's $2.64 per share. Natixis Asset holds 0.1% in Abbott Laboratories (NYSE:ABT) or 23,677 shares. Its EPS was $8.79 while outstanding shares of the company were 1.31B. Stephens Ar accumulated 0.17% or 68,769 shares. Investors measure stock performance on the basis of a company's earnings power. Proshare Advisors Limited invested in 936,513 shares.

Marshall Wace Llp increased Bank Of America (NYSE:BAC) stake by 1.87M shares to 1.96 million valued at $47.13M in 2017Q2. It also reduced Williams Companies (NYSE:WMB) stake by 650 shares and now owns 9,050 shares. Mobileye Nv Tendered (NYSE:MBLY) was raised too. (NYSE:CYT), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. The rating was maintained by RBC Capital Markets on Monday, October 3 with "Outperform". The rating was maintained by Morgan Stanley with "Equal-Weight" on Thursday, May 26. Oppenheimer has "Outperform" rating and $38 target. The firm earned "Buy" rating on Thursday, May 18 by Maxim Group. "Ultimately, through all this investigation into the company's performance the analyst decides if their stock is a "buy", sell" or hold". The stock has "Market Perform" rating by BMO Capital Markets on Thursday, September 10. Stifel Nicolaus maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, July 20. (NASDAQ:GILD) on Friday, July 29 to "Hold" rating.

Among 5 analysts covering Cytec Industries Inc. Gilead Sciences's quarterly revenue was down 9.6% compared to the same quarter past year. GILD's profit will be $2.19 billion for 10.87 P/E if the $1.67 EPS becomes a reality. Investors of record on Friday, December 15th will be paid a $0.52 dividend. Its up 0.02, from 0.91 in 2017Q1. On average, equities research analysts forecast that Gilead Sciences Inc. will post $11.75 earnings per share for the current fiscal year. 110 funds opened positions while 462 raised stakes. Community Financial Bank Na reported 13,690 shares or 0.1% of all its holdings. Clean Yield Gru, a Vermont-based fund reported 51,833 shares. Greenwood Capital Associates LLC increased its holdings in shares of Gilead Sciences by 16.8% during the 2nd quarter. (NASDAQ:GILD). Glenmede Na invested in 436,144 shares.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD). Carnegie Asset Limited Liability Corporation stated it has 0.08% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) or 196,719 shares. Greenleaf Trust owns 87,089 shares. Cornercap Inv Counsel Incorporated holds 0.66% or 55,395 shares. Parnassus Invests Ca invested 5.81% in Gilead Sciences, Inc. (NASDAQ:GILD). 50,931 were accumulated by Stevens Capital Ltd Partnership. (NASDAQ:AMKR) to report earnings on February, 12. First Dallas Securities invested in 0.28% or 5,351 shares. More interesting news about Gilead Sciences, Inc. The company reported revenue of $7.36 Billion in the same period previous year. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. The Price to Sales (P/S) ratio of the stock is 3.46, while P/B (Price to Book) stands at 3.83.

This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Wednesday, November 1st. Another trade for 5,000 shares valued at $325,114 was sold by Alton Gregg H. Therefore 60% are positive. Finally, Leerink Swann reaffirmed a "hold" rating and issued a $74.00 price target on shares of Gilead Sciences in a report on Tuesday, July 25th. The rating was upgraded by Raymond James on Monday, November 7 to "Outperform". The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has "Buy" rating given on Tuesday, September 6 by Jefferies. Piper Jaffray maintained the shares of GILD in report on Friday, July 24 with "Overweight" rating. Gilead Sciences, Inc. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. (NASDAQ:GILD) on Wednesday, September 9 with "Hold" rating. Credit Suisse has "Buy" rating and $79.0 target. The firm has "Buy" rating by Cowen & Co given on Wednesday, October 18. (NASDAQ:GILD) on Tuesday, May 30 with "Buy" rating. The rating was maintained by BMO Capital Markets with "Hold" on Monday, August 28.

Other reports by Click Lancashire

Discuss This Article